

1 **Dupilumab use is associated with protection from COVID-19 mortality: A**
2 **retrospective analysis.**

3 Donlan, A.¹, Mallawaarachchi, I.², Sasson, J.¹, Preissner, R.³, Loomba, J.⁴, Petri, W.A.^{1,5}

4

5 ¹ Division of Infectious Diseases and International Health, Department of Medicine

6 ² Department of Public Health Sciences, University of Virginia School of Medicine,

7 Charlottesville, Virginia, USA.

8 ³ Science-IT and Institute of Physiology, Charité – Universitätsmedizin Berlin,

9 corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and

10 Berlin Institute of Health, Berlin, Germany

11 ⁴ Integrated Translational Health Research Institute (iTHRIV)

12 ⁵ Department of Pathology, University of Virginia School of Medicine, Charlottesville,

13 Virginia, USA.

14

15

16

17

18

19

20

21

22

1 **Abstract:** We previously found that type 2 immunity promotes COVID-19 pathogenesis
2 in a mouse model. To test relevance to human disease we used electronic health record
3 databases and determined that patients on dupilumab (anti-IL-4R α monoclonal antibody
4 that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower
5 mortality.

6
7 **Introduction:** Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the
8 virus that causes Coronavirus Disease 2019 (COVID-19) and is currently causing a
9 devastating global pandemic. Many approaches to combat mortality involve targeting
10 inflammation, such as with the corticosteroid dexamethasone (The RECOVERY
11 Collaborative Group 2021) or the monoclonal antibody against IL-6, tocilizumab (Abani
12 et al. 2021). However, while these therapeutic options have been observed to reduce
13 mortality in patients, protection is not complete. This was exemplified by mortality due to
14 the delta variant being 12.6% during the fall 2021 surge (Iuliano et al. 202AD). More
15 recently, in hospital deaths due to the omicron variant dropped to 7.3% (Iuliano et al.
16 202AD), however, reported deaths still remain high and methods to reduce these
17 numbers are warranted. Additionally, the emergence of novel variants, such as omicron,
18 for which the vaccine is increasingly less effective against highlights that we need
19 ongoing development and identification of better therapeutic options in treating this
20 disease for those who become ill.

21 Recently, we have uncovered a causal role of Interleukin (IL)-13 in promoting
22 severe outcomes caused by infection with SARS-CoV-2, suggesting that type 2 immune
23 responses are pathogenic during COVID-19 (Donlan et al. 2021). IL-13 is often

1 associated with promoting pathology in asthma, allergies, and atopic dermatitis. In the
2 lung, pulmonary responses potentiated by IL-13 include airway hyperreactivity, mucus
3 production, smooth muscle contractility, recruitment of immune cells, and long-term
4 airway remodeling (Seibold 2018; Wills-Karp et al. 1998; Zhu et al. 1999). In acute
5 settings this results in airway restriction causing breathing difficulty and wheezing, and
6 long-term can result in decreased lung capacity and function.

7 Dupilumab is a human monoclonal antibody which blocks signaling of the closely
8 related cytokines IL-4 and IL-13 by targeting the shared alpha subunit of their receptors,
9 IL-4R α (Wenzel et al. 2013; Beck et al. 2014; Castro et al. 2018). IL-4 and IL-13 are
10 both primarily associated with type 2 responses which drive pathogenesis of asthma
11 and atopic dermatitis, for which dupilumab is approved to treat (Wenzel et al. 2013;
12 Beck et al. 2014; Castro et al. 2018). We were interested in whether dupilumab use in
13 patients who were later diagnosed with COVID-19 was associated with protection from
14 mortality due to its ability to block pathogenic IL-13 signaling. Earlier we had found in a
15 small number (81 total) of patients an association of dupilumab use with protection from
16 death due to COVID-19 (Donlan et al. 2021).

17 Here we report for over a thousand patients that dupilumab usage is associated
18 with reduced mortality compared to matched-control patients. Our findings support the
19 hypothesis that IL-13 signaling during COVID-19 is associated with more severe
20 outcomes, and that pharmacological inhibition of this pathway may be a feasible
21 therapeutic option for treating this disease.

22

23 **Methods:**

1 The N3C data transfer to NCATS is performed under a John Hopkins University
2 Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C
3 Data Enclave is managed under the authority of the NIH; information can be found at
4 <https://ncats.nih.gov/n3c/resources>.

5
6 Database and Inclusion Criteria:

7 N3C: The N3C (National COVID Cohort Collaborative) cohort was filtered to patients
8 who were COVID-19 positive based on the presence of either a SARS-CoV-2 PCR or
9 antigen-positive test results or a COVID-19 diagnosis code. The first instance of either
10 indicator in the patient's record was used as the COVID-19 index date. To account for
11 dupilumab use in COVID-19 patients that would be far removed from their diagnosis,
12 and therefore unlikely to be exerting any pharmacological effects, a cutoff was made for
13 dupilumab use within 61 days prior to the patients' index event. Using these filters, there
14 were three sub cohorts that were analyzed:

- 15
- 16 1. Controls: COVID-19 positive patients with no record of dupilumab use within
17 61 days of their index event.
 - 18 2. Dupilumab (+): Any COVID-19 patient with recorded dupilumab use within the
19 61 days preceding their index event.
 - 20 3. Dupilumab (-): COVID-19 negative patients with recorded dupilumab use.

21
22 The incidence of COVID positivity in people on dupilumab [cohort definition 1 above /
23 (definition 1 + 2)], along with 95% confidence intervals, was calculated.

1 TriNetX: Data were retrieved from the COVID-19 Research Network provided by
2 TriNetX, comprising 80 million patients from 65 health care organizations in 11 countries
3 (for database access on 12/07/2021). COVID-19 patients were identified via the ICD-10
4 code U07.1 or the presence of a SARS-CoV-2-related RNA diagnosis within the last two
5 years. Drug use was identified via RxNorm codes for dupilumab (1876376) and the lab
6 value for C-reactive protein (9063). 1:1 matching was performed for age and sex.

7

8 Matching:

9 N3C: A case-control design was used. Dupilumab (+) patients were matched to control
10 patients in a 1:5 ratio, with exact matching on gender, race and ethnicity, N3C site,
11 asthma and nearest matching on age (**Supplemental Table 1**).

12 TriNetX: Analytical tools were used to obtain baseline characteristics, balance
13 cohorts with propensity score matching and analyze outcomes of interest in the final
14 cohorts. Baseline characteristics, including demographics, diagnoses, procedures, and
15 medication were obtained. Propensity score matching was used to balance cohorts.
16 Propensity scores matched cohorts 1:1 using a nearest neighbor greedy matching
17 algorithm with a caliper of 0.25 times the standard deviation.

18

19 Outcome Definitions:

- 20 1. Hospitalized: The COVID-19 (+) test or diagnosis code occurred during a
21 hospitalization (any consecutive series of visit encounters that include an
22 inpatient stay).
- 23 2. Death: Death as recorded in medical record system from contributing sites.

1 COVID Severity: Categorical variable with following levels:

- 2 1. Mild - Outpatient
- 3 2. Moderate - Hospitalized but no ECMO or IMV
- 4 3. Severe - Hospitalized with ECMO or IMV
- 5 4. Death

6

7 Statistical Analysis:

8 N3C: Statistical analyses were performed using R studio version 3.5.1. Conditional
9 logistic regression, or exact tests in rare outcomes, was used to compare COVID-19
10 severity outcomes within the matched subset of COVID (+) patients.

11 TriNetX: Outcomes were defined as ventilation assist and death. Measures of
12 association including risk differences with their respective 95% CI's were calculated.
13 Time frame of follow-up for both groups was set to 365 days for Kaplan-Meier curves,
14 which were generated for each analysis.

15

16 **Results:**

17 The N3C and TriNetX databases were independently queried. The N3C
18 database as of August 27th 2021 included 1069 patients prescribed dupilumab for which
19 220 were subsequently diagnosed with COVID-19 within 61 days of their dupilumab
20 dose (infection rate 20.6%; 95% CI: 18.2%-23.1%). We found that dupilumab use was
21 associated with significantly fewer deaths than in the matched control group (0 vs 24
22 (2.2%); OR: 0.02) (**Table 1**).

1 Next, to support the N3C findings, we utilized the TriNetX database and filtered
2 for COVID-19 cases with (n= 937) or without (n= 1.7 million) recorded use of dupilumab
3 and performed 1:1 matching (**Supplemental Table 2**). We found that dupilumab usage
4 was associated with a lower risk of death (log-rank p-value = 0.03) (**Table 1**) for death
5 when compared to controls. Additionally, dupilumab usage in this cohort was associated
6 with decreased CRP values, indicating that inflammation was likely lower in this group.

7 8 **Discussion:**

9 Through utilization of two databases, we have found that prior dupilumab usage
10 in COVID-19 patients was associated with improved survival compared to matched
11 controls. Previous work by Ungar et al., 2022 supported this finding, where, in atopic
12 dermatitis patients dupilumab use was also associated with a reduction in severe
13 outcomes from COVID-19 (Ungar et al. 2022). We report these findings building off of *in*
14 *vivo* work supporting a causal role for IL-13 in COVID-19 pathogenesis. Due to the
15 mechanism of action of dupilumab, we hypothesize this protection, then, is mediated by
16 blocking pathogenic IL-13 signaling.

17 Retrospective analyses, such as these, provide us with large-scale data that
18 allow for smaller confidence intervals than smaller prospective studies. However, there
19 are limitations due to non-randomized groups resulting in sampling biases, difficulty
20 defining temporal boundaries, and not being able to infer causal relationships. The
21 N3C database used allowed for well-defined patient outcomes and temporal windows,
22 however small sampling size may limit the statistical power through this method.
23 Supportive analysis by TriNetX allowed for larger cohort of dupilumab (+) cases, but

1 was limited to lower matching criteria and at a 1:1 ratio. Utilization of both datasets,
2 then, provides two analyses which supported our hypothesis.

3 Identification of dupilumab as a being associated with reduction in death due to
4 COVID-19 may implicate this drug as a potential therapeutic option for patients. Future,
5 large-scale clinical trial of dupilumab use during COVID-19 will be important for
6 understanding the impact this drug may have on protecting patients from severe
7 outcomes.

8
9 Author contributions: AD wrote the manuscript. AD, IM, JL, and RB assisted with data
10 analysis. All authors contributed to discussion regarding conceptualization and design of
11 the reported studies. Authorship was determined using ICMJE recommendations.

12

13 Attribution:

14 This research was possible because of the patients whose information is included within
15 the data and the organizations and scientists who have contributed to the on-going
16 development of this community resource <https://doi.org/10.1093/jamia/ocaa196>.

17

18 Funding Sources:

19 AD, JS, and WP were supported by grants to WP from the Manning Family Foundation,
20 Ivy Foundation, Henske Family, and NIH R01 AI124214.

21 Analyses performed by IM and JL were conducted with data or tools accessed through
22 the NCATS N3C Data Enclave <https://covid.cd2h.org> and N3C Attribution & Publication
23 Policy v1.2-2020-08-25b, and supported by NCATS U24 TR002306. Support for project

1 planning and analysis was also provided by the integrated Translational Health
2 Research Institute (iTHRIV) with funding support from NCATS UL1 TR003015. RP was
3 supported by Deutsche Forschungsgemeinschaft (DFG KFO339, DFG TRR295).

4
5 Competing interests: William A. Petri, Jr. receives research funding from Regeneron,
6 Inc. which is the maker of dupilumab. The other authors declare no competing interests.

7
8 Tables:

9
10 Table 1. Disease outcomes in patients taking dupilumab compared to matched controls.
11 *; To protect patient privacy, suppressed in accordance with N3C download policy. **;
12 These data are derived directly from TriNetX and therefore not subject to N3C download
13 policy.

14
15 Table S1. Patient demographics in N3C cohort.

16
17 Table S2. Patient demographics in TriNetX cohort.

18
19 Table S3. Dupilumab use is associated with lower CRP levels of patients in TriNetX
20 database.

21

22

23

1 **References:**

- 2 Abani, Obbina, Ali Abbas, Fatima Abbas, Mustafa Abbas, Sadia Abbasi, Hakam
3 Abbass, Alfie Abbott, et al. 2021. "Tocilizumab in Patients Admitted to Hospital
4 with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform
5 Trial." *The Lancet* 397 (10285): 1637–45. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)00676-0)
6 [6736\(21\)00676-0](https://doi.org/10.1016/S0140-6736(21)00676-0).
- 7 Beck, Lisa A., Diamant Thaçi, Jennifer D. Hamilton, Neil M. Graham, Thomas Bieber,
8 Ross Rocklin, Jeffrey E. Ming, et al. 2014. "Dupilumab Treatment in Adults with
9 Moderate-to-Severe Atopic Dermatitis." *New England Journal of Medicine* 371
10 (2): 130–39. <https://doi.org/10.1056/NEJMoa1314768>.
- 11 Castro, Mario, Jonathan Corren, Ian D. Pavord, Jorge Maspero, Sally Wenzel, Klaus F.
12 Rabe, William W. Busse, et al. 2018. "Dupilumab Efficacy and Safety in
13 Moderate-to-Severe Uncontrolled Asthma." *New England Journal of Medicine*
14 378 (26): 2486–96. <https://doi.org/10.1056/NEJMoa1804092>.
- 15 Donlan, Alexandra N., Tara E. Sutherland, Chelsea Marie, Saskia Preissner, Benjamin
16 T. Bradley, Rebecca M. Carpenter, Jeffrey M. Sturek, et al. 2021. "IL-13 Is a
17 Driver of COVID-19 Severity." *JCI Insight*, June.
18 <https://doi.org/10.1172/jci.insight.150107>.
- 19 Iuliano, A. Danielle, Joan M. Brunkard, Tegan K. Boehmer, Elisha Peterson, Stacey
20 Adjei, Alison M. Binder, Stacy Cobb, et al. 2022AD. "Trends in Disease Severity
21 and Health Care Utilization During the Early Omicron Variant Period Compared
22 with Previous SARS-CoV-2 High Transmission Periods — United States,

- 1 December 2020–January 2022.” CDC.
2 <https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e4.htm#suggestedcitation>.
- 3 Seibold, Max A. 2018. “Interleukin-13 Stimulation Reveals the Cellular and Functional
4 Plasticity of the Airway Epithelium.” *Annals of the American Thoracic Society* 15
5 (Supplement_2): S98–102. <https://doi.org/10.1513/AnnalsATS.201711-868MG>.
- 6 The RECOVERY Collaborative Group. 2021. “Dexamethasone in Hospitalized Patients
7 with Covid-19.” *New England Journal of Medicine* 384 (8): 693–704.
8 <https://doi.org/10.1056/NEJMoa2021436>.
- 9 Ungar, Benjamin, Jacob W. Glickman, Alexandra K. Golant, Celina Dubin, Olga
10 Marushchak, Alyssa Gontzes, Daniela Mikhaylov, et al. 2022. “COVID-19
11 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients
12 Treated with Dupilumab.” *The Journal of Allergy and Clinical Immunology: In
13 Practice* 10 (1): 134–42. <https://doi.org/10.1016/j.jaip.2021.10.050>.
- 14 Wenzel, Sally, Linda Ford, David Pearlman, Sheldon Spector, Lawrence Sher, Franck
15 Skobieranda, Lin Wang, et al. 2013. “Dupilumab in Persistent Asthma with
16 Elevated Eosinophil Levels.” *New England Journal of Medicine* 368 (26): 2455–
17 66. <https://doi.org/10.1056/NEJMoa1304048>.
- 18 Wills-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T. Y. Neben, C. L. Karp, and D. D.
19 Donaldson. 1998. “Interleukin-13: Central Mediator of Allergic Asthma.” *Science*
20 282 (5397): 2258–61. <https://doi.org/10.1126/science.282.5397.2258>.
- 21 Zhu, Zhou, Robert J. Homer, Zhonde Wang, Qingsheng Chen, Gregory P. Geba,
22 Jingming Wang, Yong Zhang, and Jack A. Elias. 1999. “Pulmonary Expression of
23 Interleukin-13 Causes Inflammation, Mucus Hypersecretion, Subepithelial

1 Fibrosis, Physiologic Abnormalities, and Eotaxin Production.” *Journal of Clinical*
 2 *Investigation* 103 (6): 779–88. <https://doi.org/10.1172/JCI5909>.

3
 4
 5

6 **Table 1. Disease outcomes in patients taking dupilumab compared to matched**
 7 **controls.**

A. N3C				
	Controls (N=1100)	Dupilumab (N=220)	Odds Ratio	P-value
Outcome				
Hospitalized	111 (10.1%)	22 (10.0%)	0.99	0.97
Died	24 (2.2%)	0 (0.0%)	0.02	<.001
COVID-19 Severity				
Mild	982 (89.3%)	198 (90.0%)		
Moderate	83 (7.5%)	20 (9.1%)		
Severe	<20**	<20**		
Death	24 (2.2%)	0 (0.0%)		
B. TriNetX				
	Controls (N=1085)	Dupilumab (N=1085)		Log-rank p-value
Died	15*	10*		
Survival Probability	96.91%	98.84%		0.03

**; To protect patient privacy, suppressed in accordance with N3C download policy

*; These data are derived directly from Trinnetx and therefore not subject to N3C download policy.

8
 9
 10